Moreover, in prostate cancer, EZH2 can repress the expression of tumor suppressors such as DAB2IP, p16 (CDKN2A), CDK4, E-cadherin (CDH1), MSMB, Ras (KRAS), NF-κB (NFKB1), EMT regulator [21]. This evidence concerns the gene CDKN2A and prostate carcinoma.